I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 02307K-059110US

Client Ref. No.: 95-199-2

Assistant Commissioner for Patents

Washington, D.C. 20231

on Up'll Light

TOWNSEND and FOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

William M. Kavanaugh et al.

Application No.: 09/894,967

Filed: June 27, 2001

For: BINDING SITES FOR

PHOSPHOTYROSINE BINDING

DOMAINS

Examiner:

Not Yet Assigned

Art Unit:

Not Yet Assigned

COMMUNICATION

Box Sequence P.O. Box 2327 Arlington VA, 22202

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed March 15, 2002, please find enclosed a replacement copy of the computer-readable form of Sequence Listing originally filed October 29, 2001.

REMARKS

The Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed March 15, 2002, stated that the original copy of the computer-readable form of the

William M. Cavanaugh et al. Application No.: 09/894,967 Page 2

Sequence Listing filed October 29, 2001 was damaged due to treatment given to all incoming mail.

Applicants have enclosed a replacement copy of the computer-readable for of the sequence listing which is identical in content to the paper copy of the Sequence Listing filed October 29, 2001.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Andrew T. Serafini Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

ATS:adm PA 3211952 v1

SM

0300

Please type a plus sign (+) inside this box -> +

PTO/SB/21 (08-00) Approved for use inrough 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM Application Number 09/894,967 Filing Date June 27, 2001 First Named Inventor William Michael Kavanaugh Group Art Unit 1646 Fiversites Name Not yet assigned

Examiner Name Not yet assigned 1 Attorney Docket Number 02307K-059110US Total Number of Pages in This Submission ENCLOSURES (check all that apply) After Allowance Communication to Assignment Papers Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Drawing(s) Fee Attached Appeais and interferences Appeal Communication to Group Licensing-related Papers Amendment / Response (Appeal Notice, Brief, Reply Brief) Petition Routing Slip (PTO/SB/69) Proprietary Information After Final and Accompanying Petition Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Other Enclosure(s) Extension of Time Request Change of Correspondence Address (please identify below) Terminal Disclaimer Copy of Notice to Comply Express Abandonment Request Request for Refund Communication Information Disclosure Statement Sequence List (in CRF) CD, Number of CD(s) Return Postcard The Commissioner is authorized to charge any additional fees to Certified Copy of Priority Deposit Account 20-1430. Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Townsend and Townsend and Crew LLP Firm and Reg. No. 41,303 Andrew T. Serafini, Ph.D. Individual name Signature Date April 2, 2002 **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date. April 2, 2002

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

April 2, 2002

Date

Kathy Johnston

PA 3212392 v1

Signature

Typed or printed name



20350

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uscto.gov

APPLICATION NUMBER FILING RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/894,967

SAN FRANCISCO, CA 94111-3834

06/27/2001

William Michael Kayanaugh

02307K-059110US

CONFIRMATION NO. 4693

TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER **EIGHTH FLOOR**

FORMALITIES LETTER

OC000000007651894

Date Mailed: 03/15/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1,821(e), 1,821(f). 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- = To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY